Ian J. Tickle

Ian J. Tickle

Auto-generated profile, based on publicly available information

Ian J. Tickle

Astex Pharmaceuticals, 436 Science Park, Milton Road, Cambridge CB4 0QA, England

Research Focus & Metrics

Academic Career Length

52Years (1975-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2004 in Science
Verified
Journal Article
Closed access
PDF file
PWPamela A. Williams
Pamela A. Williams
JCJose Cosme
Jose Cosme
DVDijana Matak Vinković
Dijana Matak Vinković
AWAlison Ward
Alison Ward
HAHayley C. Angove
Hayley C. Angove
HJHarren Jhoti
Harren Jhoti
Cytochromes P450 (P450s) metabolize a wide range of endogenous compounds and xenobiotics, such as pollutants, environmental compounds, and drug molecules. The microsomal, membrane-associated, P450 isoforms CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP2E1, and CYP1A2 are responsible for the oxidative metabolism of more than 90% of marketed drugs. Cytochrome P450 3A4 (CYP3A4) metabolizes more drug molecules than all other isoforms combined. Here we report three crystal structures of CYP3A4: unliganded, bound to the inhibitor metyrapone, and bound to the substrate progesterone. The structures revealed a surprisingly small active site, with little conformational change associated with the binding of either compound. An unexpected peripheral binding site is identified, located above a phenylalanine cluster, which may be involved in the initial recognition of substrates or allosteric effectors.

1 October 2011 in Structure
Verified
Journal Article
Open access
RRRandy Read
Randy Read
PAPaul D. Adams
Paul D. Adams
WAW. Bryan Arendall
W. Bryan Arendall
ABAxel T. Brunger
Axel T. Brunger
PEPaul Emsley
Paul Emsley
PZPeter H. Zwart
Peter H. Zwart
This report presents the conclusions of the X-ray Validation Task Force of the worldwide Protein Data Bank (PDB). The PDB has expanded massively since current criteria for validation of deposited structures were adopted, allowing a much more sophisticated understanding of all the components of macromolecular crystals. The size of the PDB creates new opportunities to validate structures by comparison with the existing database, and the now-mandatory deposition of structure factors creates new opportunities to validate the underlying diffraction data. These developments highlighted the need for a new assessment of validation criteria. The Task Force recommends that a small set of validation data be presented in an easily understood format, relative to both the full PDB and the applicable resolution class, with greater detail available to interested users. Most importantly, we recommend that referees and editors judging the quality of structural experiments have access to a concise summary of well-established quality indicators.

1 January 1994 in Nature
Verified
Journal Article
Closed access
JEJonas Emsley
Jonas Emsley
HWHelen E. White
Helen E. White
BOBernard P. O'Hara
Bernard P. O'Hara
GOGlaucius Oliva
Glaucius Oliva
NSNarayanaswamy Srinivasan
Narayanaswamy Srinivasan
SWSteve P. Wood
Steve P. Wood

1 February 1981 in Nature
Verified
Journal Article
Closed access
PDF file
TBTom Blundell
Tom Blundell
PLPeter Lindley
Peter Lindley
LMLinda Miller
Linda Miller
DMDavid Moss
David Moss
CSChristine Slingsby
Christine Slingsby
GWGraeme Wistow
Graeme Wistow

21 December 2004 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MHMichael J. Hartshorn
Michael J. Hartshorn
CMChristopher W. Murray
Christopher W. Murray
ACAnne Cleasby
Anne Cleasby
MFMartyn Frederickson
Martyn Frederickson
ITIan J. Tickle
Ian J. Tickle
HJHarren Jhoti
Harren Jhoti

1 February 1976 in Nature
Verified
Journal Article
Closed access
PDF file
RPR. A. Pullen
R. A. Pullen
DLD. G. Lindsay
D. G. Lindsay
SWS. P. Wood
S. P. Wood
ITI. J. Tickle
I. J. Tickle
TBT. L. Blundell
T. L. Blundell
SGS. Gammeltoft
S. Gammeltoft